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ABSTRACT
Epidemiological studies have shown the importance of the metabolic syndrome. With estimation
of the metabolic syndrome, it may predict cardiovascular disease, sudden death and the presence
of some other cardiovascular risk factors. The aim of this study was to assess the metabolic
syndrome among Baluch women. Our study consisted of 120 Baluch women. Baseline data of
Baluch women, prevalence of metabolic syndrome and its components and distribution of body mass
index were determined. The mean Body Mass Index (BMI), waist circumference, systolic blood
pressure, triglyceride, High Density Lipoprotein-Cholesterol (HDL-Chol.) and fasting blood glucose
levels  were significantly higher in the subjects with metabolic syndrome. The  prevalence  of  
HDL-cholesterol, high triglyceride, high fasting glucose levels, high waist circumference and high 
blood  pressure  were  shown  to  be  33.3, 20.8, 12.5, 11.8  and  2.5%,  respectively. HDL-cholesterol
(33.3%) and high triglyceride levels (20.8%) were the most frequent characteristics of metabolic
components. The prevalence of subject with normal weight, overweight and obese BMIs were 77.5,
15 and 7.5%, respectively. About 9.17, 4.17 and 4.17% of Baluch women had three, four and five
criteria of metabolic syndrome components, respectively. This study reveals that there is a
significant difference in the metabolic syndrome components in patients with and without
metabolic syndrome. The prevalence of  HDL-cholesterol and high triglyceride in Baluch women
was highest. Definition of metabolic syndrome may help physicians to estimate, decrease and
prevent coronary heart disease and cardiovascular morbidity and mortality in subjects with
metabolic syndrome. 
Key words: Metabolic syndrome, baluch women, chabahar
INTRODUCTION
The metabolic syndrome prevalence is rising in the world. The syndrome is characterized by
obesity, glucose intolerance, hypertension and dyslipidaemia (Miranda et al., 2005). This syndrome
was clarified by Kyln for the first time in 1923 (Kylin, 1923) and in 1988, Gerald Reaven showed
the concept of metabolic syndrome. He has been explained that the clustering of hypertension,
glucose  intolerance;  high  triglycerides  and  High  Density    Lipoprotein  (HDL)  concentration
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characterized metabolic syndrome components (Reaven, 1988). Several studies have shown that
there are differences in metabolic syndrome in different ethnic groups, gender, age,
postmenopausal women and different countries (Marjani et al., 2012a, b; Marjani and Shahini,
2013; Marjani and Moghasemi, 2012; Shahini et al., 2013). It has been shown that worldwide
alterations of metabolic syndrome prevalence changes from 10-84% (Kolovou et al., 2007). Some
other studies revealed that the prevalence of metabolic syndrome alters worldwide from 8-24% and
from 7- 46.5% among men and women, respectively (Gupta  et  al.,  2003;  Ford  et  al.,  2002;
Balkau et al., 2003; Ramachandran et al., 2003). Epidemiological studies have shown the
importance of the metabolic syndrome (Shepherd et al., 1995; Downs et al., 1998; Ballantyne et al.,
2001). In developed and developing countries, the metabolic syndrome is a main health problem.
In European Americans and in Europe population, the metabolic syndrome prevalence changes
almost from 20-30% in men and women (Ford et al., 2002; Meigs et al., 2003; Cameron et al., 2004;
Qiao and The DECODE Study Group, 2006; Hildrum et al., 2007), but the prevalence of metabolic
syndrome is increasing in Asian countries (Meigs, 2000). Some studies indicated that the
prevalence of the metabolic syndrome among different age groups change. These studies showed
that this syndrome in subjects with 15 (in Japan), 12-19 (in the United States), 10-18 (in Mexico),
10-19  (in Iran)  (Duncan et al., 2004;  Esmaillzadeh  et al., 2006; Rodriguez-Moran et al., 2004; 
Saito   et   al.,  2007)  and 12-19 (US black) years old were 1, 6.4, 6.5, 10 and 4%, respectively
(Johnson et al., 2009). The pathogenesis of the metabolic syndrome is not clearly shown. Prediction
of cardiovascular disease, sudden death and cardiovascular dependent risk factors may estimate
by determination of the metabolic syndrome (Empana et al., 2007). The aim of present study was
to assess the metabolic syndrome among Baluch women.
MATERIALS AND METHODS
This study was done in the Chabahar Health Center in Sistan and Baluchestan. One hundred
and twenty Baluch women who their native language was Baluchi participated in this study in
2015. All women were directed to the Health Center in Chabahar. Women with hormone
replacement therapy, taking anti-diabetes and anti-hypertensive anti-lipidemic agents and active
smokers considered as an exclusion criteria. After 12 h fasting, a blood sample was collected.
Determination of serum fasting blood glucose, triglycerides, total cholesterol, LDL-cholesterol and
HDL-cholesterol levels in all women were carried out by commercial kits. Spectrophotometer
techniques (Model JENWAY 6105 UV/VIS) were used to determine all parameters. Metabolic
syndrome was considered if women had 3 or more of the following. 
ATP III criteria (Expert Panel on Detection, Evaluation and Treatment of High Blood
Cholesterol in Adults, 2001): 
C Serum glucose level >110 mg dLG1
C Low HDL-cholesterol <50 mg dLG1
C Serum triglycerides level >150 mg dLG1
C Systolic Blood Pressure (SBP) >130 mmHg and/or Diastolic Blood Pressure (DBP)>85 mm Hg
(Hypertension)
C Waist circumference >88 cm (Abdominal obesity)
Weight was measured with minimal clothed, using digital scales. Height was measured with
tape meter when the shoulder was in a normal position. Body Mass Index (BMI) was calculated
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when  weight    in   kilograms   divided   by   height  in  meters  squared.  BMI   with  18.5-24.9,
25.0-29.9 and $30 kg mG2 were considered as normal weight, overweight and obese, respectively
(WHO., 1998). Abdominal obesity was assessed at the point halfway between the lower border of
ribs and the iliac crest in a horizontal plane (Dalton et al., 2003). Blood pressure was determined
in sitting position from the right hand. The data were shown in percentages and mean±standard
deviation value. Analysis of data was done with SPSS-16 version software. Evaluation of results
was carried out by independent student t test. The p-value <0.05 was considered statistical
significant.
RESULTS
One hundred and twenty Baluch women were taken part in this study. The mean age of women
was 28.31±9.11 years (the age range was 15-45 years old). Mean BMI was 21.94±4.68  kg mG2.
17.5% (21/120) of women were diagnosed as having the metabolic syndrome. Table 1 shows the
baseline data of the subjects with and without the metabolic syndrome. The Mean Body Mass Index
(BMI), Waist Circumference (WC), Systolic Blood Pressure (SBP), Triglyceride (TG), High Density
Lipoprotein-Cholesterol (HDL-Chol.) and Fasting Blood Glucose (FBS) levels were significantly
higher in the subjects with metabolic syndrome (p<0.01). Table 2 shows the prevalence of metabolic
syndrome  and  the  components  of  metabolic syndrome in Baluch women. The prevalence of 
HDL-cholesterol, high triglyceride, high fasting glucose levels, high waist circumference and high
blood pressure were shown to be 33.3, 20.8, 12.5, 11.8 and 2.5%, respectively. The HDL-cholesterol
(33.3%) and high triglyceride levels (20.8%) were the most frequent characteristics of metabolic
components. Table 3 shows the distribution of Baluch women by BMI categories. The prevalence
of subject with normal weight, overweight and obesity BMIs were 77.5, 15 and 7.5%, respectively.
Table 4 shows the prevalence of three or more components of the metabolic syndrome. Our results
showed that 9.17, 4.17 and 4.17% of Baluch women had three, four and five criteria of metabolic
syndrome components, respectively.
 
Table 1: Baseline data of Baluch women (Total subjects, subjects with and without metabolic syndrome)
Total number Subjects with Subjects without
Parameters  subjects metabolic syndrome metabolic syndrome p-value
All women, No. (%) 120 (100) 21 (17.5) 99 (82.5) -
Age (years) 28.310±9.11 29.050±9.15 28.190±9.18 0.700
BMI (kg mG2) 21.940±4.68 26.050±5.91 21.060±3.90 0.001
Waist circumference (cm) 69.590±10.97 79.620±15.19 67.440±8.57 0.002
Systolic blood pressure (mm Hg) 111.80±13.20 121.00±14.10 110.00±1.23 0.000
Diastolic blood pressure (mm Hg) 69.900±9.30 73.800±11.60 69.200±86 0.096
Fasting blood sugar (mg dLG1) 90.470±19.87 112.24 ±34.17 85.920±10.91 0.002
Triglyceride (mg dLG1) 120.10±45.50 190.24±42.92 105.26±29.48 0.000
High density lipoprotein-cholesterol (mg dLG1) 50.010±11.52 35.100±7.78 53.180±9.59 0.000
Table 2: Prevalence of metabolic syndrome and the components of metabolic syndrome in Baluch women (n = 120)
Parameters Frequency (n) Percentage
Metabolic syndrome 21 17.5
Fasting blood sugar >110 mg dLG1 15 12.5
High density lipoprotein-cholesterol <50 mg dLG1 40 33.3
Triglyceride >150 mg dLG1 25 20.8
Waist circumference >88  cm 14 11.7
Systolic blood pressure >130  mg Hg/Diastolic blood pressure >85 mm Hg 3 2.5
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Table 3: Distribution of Baluch women by BMI categories (n = 120)
BMI categories Frequency (n) Percentage
Normal weight 93.00 77.5
Overweight 18.00 15.0
Obesity 9.00 7.5
Total 120.00 100.00
BMI: Body mass index
Table 4: Frequency of subjects accomplishing the criteria of metabolic syndrome 
Subject (n = 120)
--------------------------------------------------------------------------------------------------
Parameters No. %
3 criteria n 11.00 9.17
4 criteria n 5.00 4.17
5 criteria n 5.00 4.17
Total criteria n 21.00 17.5
DISCUSSION
Metabolic syndrome is an important health problem. The frequency of the metabolic syndrome
is rising worldwide. The prevalence of metabolic syndrome may alter in different countries. These
differences may be depended on lifestyle, different ethnicity and nutritional habits. Several studies
have shown that the prevalence of metabolic syndrome in developing countries (Asian countries)
was lower than developed countries (Ford et al., 2002; Qiao and The DECODE Study Group, 2006).
The prevalence of metabolic syndrome in Philippines, Malaysia, India, Turkey, Iran, Venezuela,
Brazil, Korea and Taiwan were 19, 24.2, 28.8, 33.4, 33.7, 31.2, 25.4, 31.9 and 36.6%, respectively
(Misra and Khurana, 2008; Yoon et al., 2007). Another studies on Chinese women revealed that
metabolic syndrome prevalence were 17.8% (Gu et al., 2005). Many other studies have shown that
prevalence of metabolic syndrome was 53% (Ainy et al., 2007) and 44.9% (Heidari et al., 2010). In
our study the prevalence of the metabolic syndrome is lower than some other findings (Misra and
Khurana, 2008; Yoon et al., 2007; Ainy et al., 2007; Heidari et al., 2010) which were not in
agreement with our study findings. Similar prevalence of metabolic syndrome was reported in
males and female subjects in Greece and USA studies (Athyros et al., 2005; Ramachandran et al.,
2003). Many studies have indicated that the metabolic syndrome was higher among women than
men (Ramachandran et al., 2003; Cameron et al., 2004), while in some other populations the
metabolic syndrome was found to be more common among men (Cameron et al., 2004).The
prevalence of the metabolic syndrome in our study was 17.5%. The low prevalence of metabolic
syndrome in Baluch women was almost in agreement with those of Philippines (19%) and Chinese
(17.8%) populations (Misra and Khurana, 2008; Gu et al., 2005). Metabolic syndrome prevalence
differences may be related to age distribution, nutritional statuses and ethnical differences. Several
studies have proposed that some risk factors such as no physical activity, family history of diabetes,
hypertension and cardiovascular disease and cigarette smoking may play an important role in
progressing of metabolic syndrome in developing countries (Mohebbi et al., 2012). High triglyceride
levels and  HDL-cholesterol were very common in this study. Our results showed that 20.8% of
women had triglyceride levels higher than150 mg dLG1. Relationship between serum triglyceride
levels and prevalence of coronary heart disease has indicated in some studies. High triglyceride
level may help to predict women at risk for heart diseases (Assmann et al., 1998). It has reported
that there are an association between  HDL-cholesterol levels and increased levels of serum
triglycerides (Rodriguez-Moran et al., 2004). An association between  HDL-cholesterol levels and
metabolic risk factors such as coronary heart disease were shown (Vega and Grundy, 1996). Study
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on the components of metabolic syndrome revealed that the most frequent variations of components
of metabolic syndrome was  HDL-cholesterol (33.3%), which was in agreement with the findings
of  studies  in  USA  (Heiss et al., 1980), Turkey  (Onat et al., 1992), Italy (The Research Group
ATS-RF2  of the Italian National Research Council, 1981), Canada (MacLean et al., 1999), UK
(Mann et al., 1988) and Iranian population (Sharifi et al., 2008) that the most common found was
high prevalence of  HDL-cholesterol. According  to  our  results,   a  component  of  metabolic 
syndrome  such  as HDL cholesterol  is one  of  important   risk   factors   to  predict   and   prevent 
 the   early  on set of cardiovascular disease and coronary  heart  disease  (MacLean  et al., 1999; 
Isomaa  et  al.,  2001; Meigs et al., 1997; Natali et al., 2006).
CONCLUSIONS
The result of this study reveals that there is a significant difference in the metabolic syndrome
components in patients with and without metabolic syndrome. Our findings have shown that the
prevalence of HDL-cholesterol and high triglyceride in Baluch women was highest. Definition of
metabolic syndrome may help physicians to estimate, decrease and prevent coronary heart disease
and cardiovascular morbidity and mortality in subjects with metabolic syndrome.
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